{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:04:34Z","timestamp":1781273074236,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,4]],"date-time":"2027-04-04T00:00:00Z","timestamp":1806796800000},"content-version":"am","delay-in-days":277,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30 M124165"],"award-info":[{"award-number":["P30 M124165"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016958","name":"National Institutes of Health Office of Research Infrastructure Programs","doi-asserted-by":"publisher","award":["S10OD021527"],"award-info":[{"award-number":["S10OD021527"]}],"id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006224","name":"Argonne National Laboratory","doi-asserted-by":"publisher","award":["DE-AC02-06CH11357"],"award-info":[{"award-number":["DE-AC02-06CH11357"]}],"id":[{"id":"10.13039\/100006224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["TFRI 1107-04"],"award-info":[{"award-number":["TFRI 1107-04"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118798","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:24:39Z","timestamp":1774970679000},"page":"118798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery and development of potent and selective dual NUAK\/MARK inhibitors as Hippo pathway modulators for the treatment of cancer"],"prefix":"10.1016","volume":"311","author":[{"given":"David","family":"Smil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taira","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Grouleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Hoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhananjay C.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad R.","family":"Inanlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.L.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun A.","family":"Ogunjimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Pau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona D.","family":"Chini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Kurinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Thu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Wrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Sicheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Attisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Uehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Al-awar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Methvin B.","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118798_bib1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo pathway in organ size control, tissue homeostasis, and cancer","volume":"163","author":"Yu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118798_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"YAP\/TAZ at the roots of cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118798_bib3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118798_bib4","first-page":"9","article-title":"YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches","volume":"4","author":"Piccolo","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118798_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41568-023-00579-1","article-title":"Insights into recent findings and clinical application of YAP and TAZ in cancer","volume":"23","author":"Franklin","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118798_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","article-title":"The hippo signaling pathway in development and cancer","volume":"19","author":"Pan","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2026.118798_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1692512","article-title":"Targeting TEAD in cancer","volume":"15","author":"Battina","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.118798_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.trecan.2024.10.004","article-title":"Targeting the hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?","volume":"11","author":"Paul","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2026.118798_bib9","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1038\/s41467-018-05939-2","article-title":"A feed forward loop enforces YAP\/TAZ signaling during tumorigenesis","volume":"9","author":"Gill","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118798_bib10","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1038\/s41467-018-07394-5","article-title":"NUAK2 is a critical YAP target in liver cancer","volume":"9","author":"Yuan","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118798_bib11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nature10927","article-title":"Deregulated MYC expression induces dependence upon AMPK-related kinase 5","volume":"483","author":"Liu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118798_bib12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.15252\/embr.201642455","article-title":"MARK4 inhibits hippo signaling to promote proliferation and migration of breast cancer cells","volume":"18","author":"Arash","year":"2017","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2026.118798_bib13","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1101\/gad.284539.116","article-title":"DLG5 connects cell polarity and Hippo signaling protein networks by linking PAR-1 with MST1\/2","volume":"30","author":"Kwan","year":"2016","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmech.2026.118798_bib14","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/2159-8290.CD-23-1529","article-title":"MARK2\/MARK3 kinases are catalytic codependencies of YAP\/TAZ in human cancer","volume":"14","author":"Klingbeil","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118798_bib15","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","article-title":"Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy","volume":"23","author":"Pobbati","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118798_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.chembiol.2018.11.010","article-title":"Small-molecule covalent modification of Conserved cysteine leads to allosteric inhibition of the TEAD\u2022Yap protein-protein interaction","volume":"26","author":"Bum-Erdene","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118798_bib17","article-title":"The first class of small molecules potently disrupting the YAP-TEAD interaction by direct competition","volume":"17","author":"Furet","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118798_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118798_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/EBC20240005","article-title":"NUAK: never underestimate a kinase","volume":"68","author":"Skalka","year":"2024","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ejmech.2026.118798_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.jmedchem.0c00533","article-title":"Development and therapeutic potential of NUAKs inhibitors","volume":"64","author":"Faisal","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118798_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1042\/BJ20131152","article-title":"Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases","volume":"457","author":"Banerjee","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.118798_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113080","article-title":"Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer","volume":"210","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118798_bib23","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.bmcl.2016.02.003","article-title":"Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties","volume":"26","author":"Sloman","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.118798_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-Approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118798_bib25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995\u22122021): Medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118798_bib26","article-title":"Thienyl and Cycloalkyl aminopyrimidine compounds as inhibitors of NUAK kinases, compositions and uses thereof","author":"Al-Awar","year":"2022","journal-title":"WO2022147620 A1"},{"key":"10.1016\/j.ejmech.2026.118798_bib27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17460441.2024.2385603","article-title":"Targeting polo-like kinase 1: advancements and future directions in anti-cancer drug discovery","volume":"19","author":"Raab","year":"2024","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118798_bib28","doi-asserted-by":"crossref","first-page":"20879","DOI":"10.1021\/acs.jmedchem.4c01237","article-title":"Discovery of UCB9386: a potent, selective, and brain-penetrant Nuak1 inhibitor suitable for In Vivo pharmacological studies","volume":"67","author":"Poullennec","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118798_bib29","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118798_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cub.2006.12.037","article-title":"BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo","volume":"17","author":"Steegmaier","year":"2007","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2026.118798_bib31","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1158\/0008-5472.CAN-09-0945","article-title":"Distinct concentration-dependent effects of the polo-like kinase 1\u2013Specific inhibitor GSK461364A, including differential effect on apoptosis","volume":"69","author":"Gilmartin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118798_bib32","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3389\/fonc.2020.00928","article-title":"A potential role of YAP\/TAZ in the interplay between metastasis and metabolic alterations","volume":"10","author":"Yamaguchi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.118798_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad3210","article-title":"ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling","volume":"9","author":"Wang","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2026.118798_bib34","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3892\/ol.2016.4319","article-title":"siRNA targeting YAP gene inhibits gastric carcinoma growth and tumor metastasis in SCID mice","volume":"11","author":"Zhou","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2026.118798_bib35","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP\u2013 TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.118798_bib36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mc.23374","article-title":"NUAK family kinase 2 is a novel therapeutic target for prostate cancer","volume":"61","author":"Fu","year":"2022","journal-title":"Mol. Carcinogen."},{"key":"10.1016\/j.ejmech.2026.118798_bib37","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/03946320231223310","article-title":"Cancer susceptibility 18 positively regulates NUAK family Kinase 1 expression to promote migration and invasion via sponging of miR-5586-5p in cervical cancer cells","volume":"37","author":"Wang","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118798_bib38","article-title":"NUAKs promote mTOR\/c-Myc-induced glucose and glutamine reprogramming for cell growth and metastasis in breast cancer cells","volume":"1871","author":"Raj","year":"2025","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2026.118798_bib39","article-title":"NUAKs facilitate mTOR-mediated NSCLC proliferation and metastasis by modulating glucose metabolism and inhibiting p53 activity","volume":"1872","author":"Babu","year":"2025","journal-title":"BBA - Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2026.118798_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200766","article-title":"Differential chemoproteomics reveals MARK2\/3 as cell Migration- relevant targets of the ALK inhibitor brigatinib","volume":"24","author":"Hu","year":"2023","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.118798_bib41","article-title":"Clinical data investigation identifies MARK3 as an oncogenic driver in castration-resistant prostate cancer","volume":"42","author":"Raut","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.ejmech.2026.118798_bib42","doi-asserted-by":"crossref","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","article-title":"UniProt: the universal protein knowledgebase","volume":"45","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118798_bib43","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.3390\/ijms26167810","article-title":"Integrative high-throughput RNAi screening identifies BRSK1, STK32C and STK40 as novel activators of YAP\/TAZ","volume":"26","author":"Gill","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118798_bib44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"XDS","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2026.118798_bib45","doi-asserted-by":"crossref","first-page":"14336","DOI":"10.1073\/pnas.0703012104","article-title":"Conformational instability of the MARK3 UBA domain compromises ubiquitin recognition and promotes interaction with the adjacent kinase domain","volume":"104","author":"Murphy","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118798_bib46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymeth.2011.07.005","article-title":"The Phenix software for automated determination of macromolecular structures","volume":"55","author":"Adams","year":"2011","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2026.118798_bib47","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2026.118798_bib48","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01456","article-title":"Collaboration gets the most out of software","volume":"2","author":"Morin","year":"2013","journal-title":"eLife"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:44:53Z","timestamp":1781271893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"alternative-id":["S0223523426002436"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118798","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and development of potent and selective dual NUAK\/MARK inhibitors as Hippo pathway modulators for the treatment of cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118798"}}